Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

14.02 -0.07 (-0.50%)
Official Closing Price Updated: 4:10 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,403,765
Open 14.00
Bid (Size) 13.92 (1)
Ask (Size) 14.32 (1)
Prev. Close 14.09
Today's Range 13.97 - 14.04
52wk Range 13.19 - 17.15
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
From Takeda Pharmaceutical Company Limited
Via Business Wire
Peering Into Takeda Pharmaceutical's Recent Short Interest
Via Benzinga

Performance

YTD
-11.04%
-11.04%
1 Month
+4.94%
+4.94%
3 Month
-8.66%
-8.66%
6 Month
-13.19%
-13.19%
1 Year
-3.64%
-3.64%

More News

Read More
Why Is Neurocrine Biosciences Stock Trading Lower Today?
Via Benzinga
Back To Back FDA Approval For Takeda Within Two Days, Secures Green Signal For Rare Blood Disorder Therapy
Via Benzinga
Exposures Product Safety
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Looking Into Takeda Pharmaceutical's Recent Short Interest
Via Benzinga
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
3 Promising Biotech Stocks Flying Under the Radar
Via InvestorPlace
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
A Look Into Takeda Pharmaceutical Inc's Price Over Earnings
Via Benzinga
Looking Into Takeda Pharmaceutical's Recent Short Interest
Via Benzinga
Earnings Scheduled For October 26, 2023
Via Benzinga
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
From Takeda Pharmaceutical Company Limited
Via Business Wire
A Look Into Takeda Pharmaceutical Inc's Price Over Earnings
Via Benzinga
Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone.
Via Investor's Business Daily
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
Via Talk Markets
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda's Crohn's Disease Fistulas Candidates Fall Short In Mid-Stage Study, Settles Tax Dispute With Irish Revenue Commissioners
Via Benzinga
Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years
From Takeda Pharmaceutical Company Limited
Via Business Wire
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Via Benzinga
Takeda Withdraws Lung Cancer Drug From US After Failed Confirmatory Trial
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Takeda Provides Update on EXKIVITY® (mobocertinib)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.